The Definitive Peptide Research Reference Guide — Compound Review

Use code HEALTH for 15% off at Purgo Labs
ProUnlock AI tools — $9.99/mo →
IGF-1 LR3 · For AthletesDosage Guide · 2026

IGF-1 LR3 for Athletes

IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a modified analogue of endogenous IGF-1 with a 20–30 hour half-life vs 12 minutes for the native peptide. It activates the IGF-1 receptor to drive muscle protein synthesis, satellite cell proliferation, and nutrient partitioning — making it one of the most potent anabolic peptides researched for athletic applications.

⚠ Hypoglycemia Risk.IGF-1 LR3 has insulin-like activity and can cause hypoglycemia. Always inject post-workout with carbohydrate nutrition available. Never inject fasted. Start at the lowest dose (20mcg) and assess tolerance.
WADA Status: Prohibited (S2).IGF-1 LR3 is on the WADA Prohibited List. Athletes subject to drug testing should not use this compound. This guide is for research and educational purposes only.
20–30 hrs
Half-life
vs 12 minutes for native IGF-1 — 500x longer bioavailability
20–100mcg
Research dose range
Post-workout SubQ or IM injection
4–6 weeks
Cycle length
Longer use causes receptor desensitization

Why IGF-1 LR3 Works for Athletic Performance

mTOR Activation

IGF-1 LR3 binds the IGF-1 receptor and activates the PI3K/Akt/mTOR pathway — the primary intracellular signaling cascade for muscle protein synthesis. This directly drives lean mass accretion in response to resistance training.

Satellite Cell Proliferation

Activates muscle satellite cells (stem cells), promoting their proliferation and differentiation into new muscle fibers. This is the mechanism by which IGF-1 LR3 can produce hyperplasia (new muscle fibers) in addition to hypertrophy (larger existing fibers).

Nutrient Partitioning

Increases glucose uptake in muscle tissue and promotes amino acid transport into muscle cells, directing nutrients toward muscle protein synthesis rather than fat storage — particularly effective in the post-workout anabolic window.

IGFBP Resistance

The LR3 modification reduces binding affinity for IGF-binding proteins (IGFBPs) by ~500x. Since IGFBPs normally sequester ~99% of circulating IGF-1, this modification dramatically increases the proportion of bioavailable, active peptide.

IGF-1 LR3 Dosage Protocol for Athletes

LevelDoseTimingCycle LengthNotes
Beginner20–40mcg/dayPost-workout SubQ/IM4 weeksAssess hypoglycemia tolerance; have carbs available
Intermediate50–80mcg/dayPost-workout SubQ/IM4–6 weeksMost common athletic protocol; strong anabolic effect
Advanced80–100mcg/dayPost-workout bilateral IM4–6 weeksMaximum research dose; significantly elevated hypoglycemia risk
Off cycleNone4–6 weeks4–6 weeksAllow receptor desensitization to reset

IGF-1 LR3 from Purgo Labs

≥99% purity, third-party COA verified, cGMP facility.

Use code HEALTH for 15% off.

Shop IGF-1 LR3

Frequently Asked Questions

What is the best IGF-1 LR3 dose for athletes?

The most commonly researched dose range is 20–100mcg per day, injected subcutaneously or intramuscularly. Beginner protocols typically start at 20–40mcg/day. Intermediate protocols use 50–80mcg/day. Doses above 100mcg/day significantly increase the risk of hypoglycemia and are not recommended. Most athletes cycle IGF-1 LR3 for 4–6 weeks due to receptor desensitization.

When should athletes inject IGF-1 LR3?

Post-workout injection is the most common approach — the anabolic window immediately after training maximizes nutrient partitioning and muscle protein synthesis. Some athletes inject bilaterally into the trained muscle groups (intramuscular) to direct the anabolic effect locally. Fasting injection is avoided due to hypoglycemia risk; always inject with food or post-workout nutrition available.

How does IGF-1 LR3 differ from regular IGF-1?

IGF-1 LR3 has an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus. This modification reduces its binding affinity for IGF-binding proteins (IGFBPs) by ~500x, meaning more of the peptide remains in its active, unbound form. The result is a half-life of 20–30 hours vs ~12 minutes for regular IGF-1, and significantly greater bioavailability.

Does IGF-1 LR3 cause hypoglycemia?

Yes — hypoglycemia is the primary risk with IGF-1 LR3. IGF-1 has insulin-like activity and can cause blood glucose to drop, particularly when injected in a fasted state or at high doses. Always inject post-workout with carbohydrate-containing nutrition available. Symptoms of hypoglycemia include dizziness, sweating, confusion, and shakiness. Start at the lowest effective dose (20mcg) and assess tolerance.

How long should athletes cycle IGF-1 LR3?

Most protocols recommend 4–6 week cycles with 4–6 weeks off. Longer continuous use leads to IGF-1 receptor downregulation (desensitization), reducing effectiveness. The off-cycle period allows receptor sensitivity to reset. Some athletes time cycles to coincide with high-intensity training blocks or competition preparation phases.

Is IGF-1 LR3 prohibited in sports?

Yes. IGF-1 and its analogues (including LR3) are classified under WADA's Prohibited List as peptide hormones (S2 category). Athletes subject to drug testing by WADA, USADA, or any major sports federation should not use IGF-1 LR3. This guide is for research and educational purposes only.

Research Purposes Only. IGF-1 LR3 is a research chemical not approved by the FDA for human use. It is prohibited by WADA. This content is for educational purposes only and does not constitute medical advice.

Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.